Literature DB >> 28941155

Women who carry a fragile X premutation are biologically older than noncarriers as measured by telomere length.

Igor Albizua1, Benjamin L Rambo-Martin1, Emily G Allen1, Weiya He1, Ashima S Amin1, Stephanie L Sherman1.   

Abstract

Women who carry a fragile X premutation, defined as having 55-200 unmethylated CGG repeats in the 5' UTR of the X-linked FMR1 gene, have a 20-fold increased risk for primary ovarian insufficiency (FXPOI). We tested the hypothesis that women with a premutation + FXPOI have shorter telomeres than those without FXPOI because they are "biologically older." Using linear regression, we found that women carrying a premutation (n = 172) have shorter telomeres and hence, are "biologically older" than women carrying the normal size allele (n = 81). Strikingly, despite having shorter telomeres, age was not statistically associated with their telomere length, in contrast to non-carrier controls. Further, telomere length within premutation carriers was not associated with repeat length but was associated with a diagnosis of FXPOI, although the latter finding may depend on FXPOI age of onset.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  FMR1; FXPOI; FXTAS; fragile X premutation; telomere length

Mesh:

Substances:

Year:  2017        PMID: 28941155      PMCID: PMC5650511          DOI: 10.1002/ajmg.a.38476

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  57 in total

Review 1.  FMR1 and the continuum of primary ovarian insufficiency.

Authors:  Shannon D Sullivan; Corrine Welt; Stephanie Sherman
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

2.  Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome.

Authors:  Maria-Isabel Tejada; Eva García-Alegría; Amaia Bilbao; Cristina Martínez-Bouzas; Elena Beristain; Marisa Poch; Maria A Ramos-Arroyo; Blanca López; Isabel Fernandez Carvajal; Maria-Pilar Ribate; Feliciano Ramos
Journal:  Menopause       Date:  2008 Sep-Oct       Impact factor: 2.953

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

5.  Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases.

Authors:  Zukhrofi Muzar; Patrick E Adams; Andrea Schneider; Randi J Hagerman; Reymundo Lozano
Journal:  Intractable Rare Dis Res       Date:  2014-11

6.  Effect of long-term hormone therapy on telomere length in postmenopausal women.

Authors:  Duk-Chul Lee; Jee-Aee Im; Jeong-Ho Kim; Hye-Ree Lee; Jae-Yong Shim
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

7.  Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects.

Authors:  Athanase Benetos; Jeffrey P Gardner; Mahmoud Zureik; Carlos Labat; Lu Xiaobin; Chris Adamopoulos; Mohamed Temmar; Kathryn E Bean; Frédérique Thomas; Abraham Aviv
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

8.  Examination of reproductive aging milestones among women who carry the FMR1 premutation.

Authors:  E G Allen; A K Sullivan; M Marcus; C Small; C Dominguez; M P Epstein; K Charen; W He; K C Taylor; S L Sherman
Journal:  Hum Reprod       Date:  2007-06-22       Impact factor: 6.918

Review 9.  Telomeres and aging.

Authors:  Geraldine Aubert; Peter M Lansdorp
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

10.  Race, Ethnicity, Psychosocial Factors, and Telomere Length in a Multicenter Setting.

Authors:  Shannon M Lynch; M K Peek; Nandita Mitra; Krithika Ravichandran; Charles Branas; Elaine Spangler; Wenting Zhou; Electra D Paskett; Sarah Gehlert; Cecilia DeGraffinreid; Timothy R Rebbeck; Harold Riethman
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.